Related Experiment Video

Updated: Sep 23, 2025

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

13.7K

[Immunotherapy Based on Tumor Microenvironment in Renal Cell Carcinoma]

Song-Chen Han, Hua-Qi Yin, Tao Xu

    Zhongguo Yi Xue Ke Xue Yuan Xue Bao. Acta Academiae Medicinae Sinicae
    |May 11, 2022
    PubMed

    Insights

    Renal cell carcinoma (RCC) treatments face resistance. Advances in understanding the tumor microenvironment (TME) are paving the way for combined targeted therapy and immunotherapy for advanced RCC.

    Area of Science:

    • Uro-oncology
    • Cancer immunology
    • Translational oncology

    Background:

    • Renal cell carcinoma (RCC) is a lethal urological cancer where distant metastasis is the primary cause of death.
    • Targeted agents have improved prognosis, but therapeutic resistance remains a significant challenge for RCC patients.
    • Immune checkpoint inhibitors and immunotherapy targeting the tumor microenvironment (TME) offer new clinical applications for advanced RCC.

    Purpose of the Study:

    • To review the characteristics of the tumor microenvironment (TME) in renal cell carcinoma (RCC).
    • To identify candidate predictive biomarkers for therapeutic response in RCC.
    • To explore potential targets for future drug development in advanced RCC.

    Main Methods:

    • Literature review of studies on renal cell carcinoma (RCC) and tumor microenvironment (TME).
    • Analysis of current targeted therapy and immunotherapy strategies for RCC.
    • Synthesis of information on biomarkers and potential therapeutic targets.

    Main Results:

    • The tumor microenvironment (TME) plays a critical role in the progression and treatment response of RCC.
    • Combination strategies involving targeted therapy and immunotherapy show promising results for advanced RCC.
    • Understanding TME characteristics is crucial for developing effective predictive biomarkers and novel therapeutic targets.

    Conclusions:

    • The combination of targeted therapy and immunotherapy represents a promising future direction for managing advanced renal cell carcinoma (RCC).
    • Further research into TME characteristics, biomarkers, and novel drug targets is essential for improving patient outcomes in RCC.
    • Personalized therapeutic approaches based on TME insights may overcome treatment resistance in RCC.
    Keywords:
    biomarkercarcinoma-associated fibroblastsimmunotherapyrenal cell carcinomatumor microenvironment

    More Related Videos

    Microfluidic Co-culture of Renal Healthy and Tumor Epithelium to Model Kidney Cancer Progression06:29

    Microfluidic Co-culture of Renal Healthy and Tumor Epithelium to Model Kidney Cancer Progression

    Published on: January 31, 2025

    818
    Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells09:32

    Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

    Published on: February 8, 2018

    14.8K

    Related Concept Videos

    Tumor Immunotherapy01:27

    Tumor Immunotherapy

    Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
    681
    The Tumor Microenvironment02:17

    The Tumor Microenvironment

    Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
    6.8K
    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against...
    7.9K
    Combination Therapies and Personalized Medicine02:50

    Combination Therapies and Personalized Medicine

    Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
    The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
    5.1K